Given that elevated tau-PET is closely linked to cognitive decline and clinical progression,18,19 even in cognitively unimpaired older adults compared with those with only elevated Aβ,9,10 it is expected that only a small proportion of the sample (here 11% to 12% in both cohorts) would be resilient to AD pathology (ie, having higher tau-PET levels than expected for their clinical stage). This evidence concerns the gene MAPT and Alzheimer disease.